Intended for healthcare professionals

What is new in methotrexate for psoriasis?

Claire Martyn-Simmons and Catherine Smith
Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects approximately 2–3% of the world’s population. For many patients, it is a lifelong condition; 20–30% of patients will have severe psoriasis and will often require systemic therapy to achieve disease control. Methotrexate was first introduced as a treatment for psoriasis over 50 years ago and, in spite of the development of many new biological treatments, it remains the gold standard systemic therapy for psoriasis in Europe.
Dermatology in practice 2009; 17(2): 4–7
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)